Introduction {#s1}
============

Schizophrenia is a chronic and severe mental disorder with a lifetime prevalence of around 1% globally.[@R1] It has a profound impact on individuals, families and society. Over half of the patients with schizophrenia suffer from intermittent psychosis and approximately one-fifth of them have chronic symptoms, and mental and physical disability.[@R2] Schizophrenia is characterised by diverse psychopathology with symptoms that are commonly divided into five dimensions: positive symptoms, negative symptoms, cognitive symptoms, aggressive symptoms and affective symptoms.[@R3] Depressive symptoms (seen as one end on the spectrum of affective symptoms) frequently accompany schizophrenia, may be part of the prodromal symptomology, following an acute episode, or occur between psychotic episodes.[@R4] Although not as dramatic as positive and aggressive symptoms, it should be noted that the depressive symptoms of schizophrenia have been reported to be associated with various less favourable outcomes in schizophrenia.[@R5] These include poorer responses to medication, greater impairments in social and vocational functioning, more personal stigma, higher risk of discontinuation of medication and rehospitalisation, longer durations of hospitalisation, greater family and societal burden, more negative life events and even increased rate of suicide attempts and completed suicides.[@R8] Unfortunately, less attention is paid to depressive symptoms than other symptom domains of schizophrenia. To make matters worse, it is quite difficult to distinguish a depressive syndrome from other diagnoses with overlapping features, in particular the negative symptoms commonly seen in schizophrenia. The negative syndrome includes a number of clinical presentations which are similar to components of the depression syndrome, such as anhedonia, anergia, alogia, blunted affect, social withdrawal and loss of motivation, which may confuse doctors.[@R11] Accordingly, patients may not receive adjunctive antidepressant treatment in good time. Therefore, a biomarker for depressive syndromes is of great interest.

Leptin, encoded by the obese (ob﻿) gene, is a 16 kD protein primarily synthesised and secreted by adipocytes. It exerts multiple biological functions by binding to its receptors. Initially, leptin was found to inhibit food intake and promote energy consumption and therefore it was known as an antiobesity hormone.[@R13] However, the function of leptin has recently been broadened into involvement of mood disorders, in particular depression.[@R14] Ample literature has indicated leptin as a novel modulator of depressive mood. Animal studies showed that leptin receptors were highly expressed in mood-related brain regions including the amygdala, cortex and hippocampus.[@R18] Clinical studies found decreased leptin levels in patients with major depression and observed increases in leptin levels accompanied with improvements in depressive symptoms following antidepressant treatment.[@R19] Therefore, plasma leptin may serve as a peripheral biomarker for the differential diagnosis and evaluation of depressive syndromes in schizophrenia.

In light of the findings mentioned above, we hypothesised that the plasma leptin levels may be associated with depressive symptoms in chronic schizophrenia. Therefore, our present study aims to investigate (1) whether plasma leptin levels were altered in patients with schizophrenia; (2) whether there was a relationship between plasma leptin levels and psychopathological parameters, particularly the depressive subscore.

Methods {#s2}
=======

Subjects {#s2-1}
--------

Eighty-five inpatients were recruited from January 2017 to June 2017, and 52 healthy controls matched for gender, age and body mass index (BMI) were recruited by advertisement ([figure 1](#F1){ref-type="fig"}).

![The flow chart of the study.](gpsych-2018-100018f01){#F1}

The inclusion criteria for patients were the following: (1) meeting diagnostic criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition based on the Mini-International Neuropsychiatric Interview; (2) aged 18--80, ethnically Han Chinese; (3) had a duration of schizophrenia ≥4 years; (4) experienced multiple psychotic episodes ≧2 times; and (5) on stable antipsychotic treatment with either chlorpromazine or olanzapine ≧12 months (without dose change for at least 30 days). None of the participants in the control group had a personal or family history of psychotic disorders as assessed by two experienced psychiatrists.

The exclusion criteria were the following: (1) were diagnosed with schizoaffective disorder, mental retardation, substance abuse, cognitive disorders or other mental disorder; (2) had a severe neuroendocrine or metabolic medical condition, or immunologic alterations other than those related to antipsychotics; and (3) were pregnant or nursing.

After strict screening, 75 patients were included in our study while 10 were excluded for the following reasons: six patients declined to participate in, three patients had metabolic or neuroendocrine disease and one patient was diagnosed with schizoaffective disorder. Fifty healthy controls were included in the study while two were excluded because of physical condition (as shown in [figure 1](#F1){ref-type="fig"}).

All participants provided written informed consent. Demographic data, physical examination and blood samples were collected from all subjects.

Clinical evaluation {#s2-2}
-------------------

The patients' psychopathology was evaluated by two psychiatrists with clinical experience for more than or equal to 5 years, using the Positive and Negative Syndrome Scale (PANSS)[@R23] and the Brief Psychiatric Rating Scale (BPRS).[@R23] Training consistency of PANSS and BPRS was conducted between the two psychiatrists before the evaluation. Thereafter, an intraclass correlation coefficient ≧0.8 was maintained at repeated evaluation in this study.

Although the items of PANSS were originally grouped into three subscales,[@R25] factor analyses indicated that a five-factor model may better characterise PANSS data: positive factor (items P1, P3, P5, G9), negative factor (items N1, N2, N3, N4, N6, G7), cognitive factor (items P2, N5, G11), excited factor (items P4, P7, G8, G14) and depressed factor (items G2, G3, G6).[@R26]

Measurement of plasma leptin, glucose and lipid profiles {#s2-3}
--------------------------------------------------------

All blood samples were collected from subjects between 07:00 and 09:00 following an overnight fast. Plasma was then separated, aliquoted and stored at −80°C. Plasma leptin levels were measured in triplicate by using commercial ELISA kit (R&D Systems, USA). All samples were assayed by the same technician who was blind to the clinical status of the samples. The interassay and intra-assay coefficients of variability for leptin were 3.4% and 4.5%, respectively.

Statistical analysis {#s2-4}
--------------------

Statistical analysis was performed by using the Statistical Package for Social Sciences (SPSS, V.23.0; IBM). The Kolmogorov-Smirnov test was used to examine the normal distribution of data. Because of the non-normal distribution, the concentration of leptin was converted into lg (leptin) before further statistical analysis. Independent samples t-test for continuous variables and *χ* ^2^ test for categorical variables were respectively used to compare demographic data and clinical variables between groups. Analysis of covariance (ANCOVA) was further used to control for confounding effects of gender, age and BMI on leptin levels. Spearman's r test was used to examine the correlation between leptin and psychopathological variables when controlled for gender, age and BMI. Multiple stepwise regression analysis was then used to identify significant predictive variables associated with psychopathological variables when controlled for gender, age and BMI. In addition, Bonferroni correction was applied to adjust for multiple testing. All p values were two tailed with the significance level set at 0.05.

Results {#s3}
=======

Demographic data of patients with schizophrenia and healthy controls {#s3-1}
--------------------------------------------------------------------

A total of 75 patients with schizophrenia and 50 healthy subjects were included in this study. One patient was excluded from the analysis as the concentration of his plasma leptin level did not fall within 3 SDs of the mean and was therefore considered an outlier. Hence all analyses were performed on 74 patients and 50 controls. As shown in [table 1](#T1){ref-type="table"}, no significant differences in gender, age and BMI were found between the patients and controls.

###### 

Demographic data and clinical characteristics of the patients with schizophrenia and healthy controls

                                                                   Schizophrenia   Healthy controls   *t* or *χ* ^*2*^   P values
  ---------------------------------------------------------------- --------------- ------------------ ------------------ ----------
  n                                                                74              50                                    
  Gender                                                                                                                 
   Male (%)                                                        50/75 (66.7)    35/50 (33.3)       0.153              0.696
   Female (%)                                                      20/75 (70.0)    15/50 (30.0)                          
  Age (years)                                                      57.0 (10.3)     55.0 (9.6)         0.135              0.893
  BMI (kg/m^2^)                                                    24.3 (3.4)      23.9 (2.9)         0.083              0.934
  Years of education                                               8.8 (2.2)                                             
  Age of onset (years)                                             28.2 (9.1)                                            
  Duration of schizophrenia (years)                                28.8 (12.8)                                           
  DUP (months)                                                     48.1 (80.2)                                           
  Number of episodes                                               5.3 (3.2)                                             
  Daily antipsychotic dosage (mg) (chlorpromazine equivalents\*)   280.7 (113.3)                                         
  PANSS total score                                                74.6 (16.2)                                           
   Positive subscale                                               10.2 (4.4)                                            
   Negative subscale                                               27.4 (7.9)                                            
   General psychopathology subscale                                37.3 (9.8)                                            
  BPRS total score                                                 43.6 (10.3)                                           

\*The chlorpromazine equivalents were calculated as described by Gray *et al*.[@R42]

BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; DUP, duration of untreated psychosis; PANSS, Positive and Negative Syndrome Scale.

Plasma leptin levels in patients with schizophrenia and healthy controls {#s3-2}
------------------------------------------------------------------------

Logarithmic transformed plasma leptin levels (lg leptin) were significantly higher in patients with schizophrenia than in healthy controls ([figure 2](#F2){ref-type="fig"}). When gender, age and BMI were added as potential confounding covariates to ANCOVA, the differences between groups remained significant (*F*=25.79, df=1, *p*\<0.001).

![Logarithmic transformed plasma leptin levels (lg leptin) in patients with schizophrenia (n=74) and healthy controls (n=50). The sample means are indicated by the black bars. Plasma lg leptin levels were significantly higher in patients with schizophrenia than healthy controls.](gpsych-2018-100018f02){#F2}

Association between leptin levels and psychopathology in schizophrenia {#s3-3}
----------------------------------------------------------------------

When controlled for gender, age and BMI, partial correlation analysis indicated a significantly negative association between plasma leptin levels and the PANSS depression factor scores (*r*=−0.255, Bonferroni corrected *p*=0.028, as shown in [table 2](#T2){ref-type="table"}).

###### 

Partial correlations between leptin levels and clinical variables in patients with schizophrenia, controlled for gender, age and BMI (Spearman\'s r) (n=74)

                      Correlation coefficient   P values
  ------------------- ------------------------- -------------
  PANSS total score   −0.039                    0.745
   Positive factor    0.141                     0.230
   Negative factor    −0.970                    0.412
   Cognitive factor   −0.045                    0.707
   Excited factor     0.139                     0.236
   Depressed factor   −0.255                    0.028**\***
  BPRS total score    −0.074                    0.535

\*Indicated the Bonferroni corrected p value, *p*\<0.05.

BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; PANSS, Positive and Negative Syndrome Scale.

Furthermore, a multiple stepwise regression was run to predict the PANSS depression factor with leptin levels and demographics including years of education, age of onset, duration of schizophrenia, duration of untreated psychosis, number of episodes and daily antipsychotic dosage. When adjusted for gender, age and BMI, leptin levels were identified as a significant predictor for the PANSS depression factor (*β*=−0.33, *t*=−2.32, *p*=0.024) (*β*=−0.26, *t*=−1.79, *p*=0.032).

According to the criteria of PANSS depression factor score \>3, forty-seven of the 74 patients with schizophrenia had depressive symptoms. In the depressive symptom group, correlation analysis (*r*=−0.303, Bonferroni corrected *p*=0.038, as shown in [table 3](#T3){ref-type="table"}) and regression analysis (*β*=−0.26, *t*=−1.79, *p*=0.032) further confirmed that plasma leptin levels were significantly negatively associated with the PANSS depressed factor.

###### 

Partial correlations between leptin levels and clinical variables in schizophrenia with depressive symptoms, controlled for gender, age and BMI (Spearman\'s r) (n=47)

                      Correlation coefficient   P values
  ------------------- ------------------------- -------------
  PANSS total score   0.008                     0.958
   Positive factor    0.23                      0.121
   Negative factor    −0.069                    0.644
   Cognitive factor   0.069                     0.644
   Excited factor     0.373                     0.352
   Depressed factor   −0.303                    0.038**\***
  BPRS total score    −0.04                     0.789

\*Indicated the Bonferroni corrected p value, *p*\<0.05.

BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; PANSS, Positive and Negative Syndrome Scale.

Discussion {#s4}
==========

Main findings {#s4-1}
-------------

This study had two main findings. (1) Plasma leptin levels were significantly increased in patients with schizophrenia compared with the healthy controls despite controlling for gender, age and BMI. (2) Plasma leptin levels were significantly negatively associated with the PANSS depressed factor but not with other factor components.

In this study, we observed significantly higher plasma leptin levels in patients with chronic schizophrenia, which was in agreement with previous studies.[@R16] Early research focused primarily on the relationship between leptin levels and weight changes associated with antipsychotic treatment. Many studies reported that the elevated leptin levels in patients with schizophrenia were largely dependent on weight gain and BMI. However, few of these studies considered that a difference in BMI existed between groups when they compared leptin levels. On the contrary, gender, age and BMI were taken into account, and the difference of leptin levels between the patients and controls remained significant. Likewise, Kim and colleagues recently found that plasma leptin levels tended to be higher in patients with schizophrenia than in age-matched and BMI-matched healthy controls.[@R30] A recent meta-analysis also found that schizophrenia was associated with elevated blood leptin levels compared with controls, but the difference in leptin levels between groups was not moderated by BMI. Taken together, these studies suggest that leptin levels may be associated with multiple factors, for example, the psychopathology of schizophrenia, different phases of illness and lifestyles.

In our present study, it was further found that there was a significant negative correlation between plasma leptin levels and the PANSS depressed factor subscore in patients with schizophrenia. Previous studies observed decreased plasma leptin levels in patients with or without comorbid major depression compared with controls.[@R31] Furthermore, studies found that the negative relationship between leptin levels and the severity of depressive symptoms was independent of body weight or BMI.[@R28] In consistency with these findings, our study also found a link between leptin levels and depressive symptoms in patients with schizophrenia after controlling for BMI.

Limitations {#s4-2}
-----------

Several limitations of this study should be noted. First, due to the nature of cross-sectional studies, the patients' baseline information was unknown (eg, plasma leptin levels, psychopathological symptoms and previous medication use) and therefore the results obtained in this study may be confounded. Second, as the sample size is small and leptin level is fluctuated, our findings should be accordingly considered as preliminary exploration. Last, it is worth mentioning that the depressed factor used in the present study is derived from the five-factor model of PANSS scale, which is used for symptomatology. A specific depression scale such as Hamilton Depression Rating Scale may have been a better choice. Therefore, in order to get a conclusive and not just suggestive result, the relationship between leptin and depressive symptomology in schizophrenia deserves further investigation using a specific depression scale in a large-scale longitudinal study, or even a randomised, double-blind and parallel controlled clinical trial.

Implications {#s4-3}
------------

Different theories have been proposed in the literature to explain the negative relationship between plasma leptin levels and the depressive symptoms.

First, leptin may be involved in regulation of serotonin (5-HT) and dopamine (DA), which are the key neurotransmitters in the classic aetiological hypothesis of depression. Previous studies have found that intraperitoneal administration of leptin dose dependently significantly increased serum 5-HT levels,[@R35] while leptin-deficient *ob/ob* mice exhibited impaired DA functions and decreased DA release.[@R36] Second, leptin may have direct and indirect neurotrophic effects, which are disrupted in depression. Previous studies showed that leptin administration elevated the expression of brain-derived neurotrophic factor, one of the most important neurotrophic factors.[@R37] Leptin-deficient *ob/ob* mice showed decreased weight overall for the whole brain and decreased volume of specific brain regions, while these neurodegenerative changes were partially reversed by leptin treatment.[@R35] Third, leptin may be a potent inhibitor of the hypothalamic-pituitary-adrenal axis, which is overactive in depression.[@R41]

To our knowledge, this is the first study to explore the relationship between leptin levels and depressive symptoms in schizophrenia, while previous studies focused mainly on major depressive disorder. If our results could be confirmed in further large-scale longitudinal studies, plasma leptin level would probably serve as a promising predictor for depressive symptoms in schizophrenia.
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